UNSPSC 51201627: Haemophilus B vaccine

This classification denotes a vaccine for a species of haemophilus found on the mucous membranes of humans and a variety of animals, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LUY6P8763W. The US Centers for Disease Control recognizes this preparation under Concept Code 51 and CDC Code System OID 2.16.840.1.113883.12.292.

UNSPSC 51201627 Haemophilus B vaccine is a Commodity code that nominally covers immunization products, though the recent solicitation activity under this code involves a different vaccine product. The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with objections due August 3, 2026 at 10:00 a.m. CST. This is a notice of proposed sole source purchase rather than a standard competitive solicitation; any entity objecting to the sole source classification must submit written notice with detailed explanation and supporting documentation demonstrating that an alternative vendor can supply the vaccine. If the Mississippi State Department of Health substantiates objections showing the commodity is available from alternative sources, it will withdraw the sole source publication and conduct an advertised competitive bid or selection process. Should the department determine only one source exists, it will appeal to the Public Procurement Review Board, which requires the department to bear the burden of proof that the vaccine is available exclusively from Sanofi Pasteur.

The recent opportunity block reflects limited activity under this code, with only one recent solicitation. The Mississippi State Department of Health is the identified issuing body. The notice does not specify quantity, contract term, estimated value, or pricing, limiting visibility into the scale of procurement. The mismatch between the code's nominal scope (Haemophilus B vaccine) and the actual solicitation (Yellow Fever Vaccine) suggests either tagging inconsistency or that this code spans a broader range of vaccine products than the name alone indicates. Firms responding to vaccine solicitations from state health departments should monitor for sole source notices and understand the objection process required by public procurement review boards in jurisdictions where sole source determinations are challenged.